A single-arm exploratory clinical trial is the first to evaluate the safety and efficacy of sequential anti-CD19 and anti-BCMA CAR-T cell infusion, followed by lenalidomide maintenance after autologous stem-cell transplantation in ten high-risk newly diagnosed multiple myeloma patients.
[American Journal of Hematology]